A Study to Evaluate a Supplement Combination in Supporting Weight Loss, Metabolic Health, and Quality of Life (RESMRESG101)

May 28, 2026 updated by: Able Biolabs, LLC

A Consumer Study to Evaluate the Efficacy of a Postbiotic and Prebiotic Supplement Combination in Supporting Weight Loss, Metabolic Health, and Quality of Life

This consumer-use study evaluates the effects of a combined postbiotic and prebiotic supplement regimen on appetite control, cravings, metabolic health, energy, and quality of life in adults aged 18-65 years with a body mass index (BMI) between 25 and 30.

Participants will consume one capsule of resM™ GLP-1 Postbiotic and one scoop of resG prebeet ENERGY Prebiotic daily for 60 days. Data will be collected through daily check-ins, weekly surveys, and quality-of-life questionnaires administered through the Chloe mobile application.

The primary objective is to evaluate changes in appetite control and food cravings over 60 days of supplementation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The GLP-1 Optimizer Bundle combines resM™ GLP-1 Postbiotic and resG prebeet ENERGY Prebiotic to support appetite control, cravings, metabolic health, energy, and lifestyle behaviors.

This is a prospective, open-label, single-arm consumer-use study conducted over 60 days in approximately 20 adults aged 18-65 years with BMI between 25 and 30.

Participants will consume:

one capsule of resM™ GLP-1 Postbiotic daily one scoop of resG prebeet ENERGY Prebiotic daily

Assessments will be collected electronically through the Chloe mobile application and include:

appetite and cravings surveys energy and mood assessments quality-of-life questionnaires lifestyle habit surveys consumer satisfaction assessments

The study aims to evaluate consumer-reported changes associated with daily supplementation and lifestyle guidance.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35203
        • Able Biolabs, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Adults aged 18-65 years BMI between 25 and 30 Generally healthy Willing to comply with study procedures Access to smartphone or internet-enabled device for electronic questionnaires

Exclusion Criteria Pregnant, planning pregnancy, or lactating History of bariatric surgery Prescription weight loss medication use within the past 90 days Current GLP-1 drug use History of substance abuse within the past 6 months Current use of supplements containing overlapping active ingredients Significant medical condition that may interfere with study participation or interpretation of results

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Supplement Bundle
resM™ GLP-1 Postbiotic, and resG prebeet ENERGY Prebiotic
Dietary supplement: Combination Prebiotic and Postbiotic
Participants will take a combined dosage of prebiotic and postbiotic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Appetite Control and Food Cravings Survey Scores Over 60 Days
Time Frame: Baseline through Day 60
Participant-reported appetite control and food cravings will be assessed using daily and weekly questionnaires administered through the Chloe mobile application. Survey responses will evaluate changes in hunger, cravings, satiety, and eating behaviors over the study period.
Baseline through Day 60

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Energy and Mood Survey Scores Over 60 Days
Time Frame: Baseline through Day 60
Participant-reported energy levels and mood will be assessed using weekly questionnaires administered through the participant management application.
Baseline through Day 60
Change in Quality-of-Life Questionnaire Responses Over 60 Days
Time Frame: Baseline, Day 30, and Day 60
Quality-of-life assessments will evaluate participant-reported physical well-being, lifestyle habits, and overall satisfaction during the study period.
Baseline, Day 30, and Day 60
Participant Satisfaction and Willingness to Continue Product Use at Day 60
Time Frame: Day 60
End-of-study surveys will assess participant satisfaction, perceived benefits, and willingness to continue using the supplement combination.
Day 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Able Biolabs, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 20, 2025

Primary Completion (Actual)

May 5, 2026

Study Completion (Actual)

May 5, 2026

Study Registration Dates

First Submitted

April 29, 2026

First Submitted That Met QC Criteria

May 19, 2026

First Posted (Actual)

May 27, 2026

Study Record Updates

Last Update Posted (Actual)

June 1, 2026

Last Update Submitted That Met QC Criteria

May 28, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ABL-032502

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Combination Prebiotic and Postbiotic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe